Previous 10 | Next 10 |
– Live webcast with members of Palisade Bio management on Tuesday, April 16 th at 12:00 PM ET Carlsbad, CA, April 11, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio” or the “Company...
2024-04-10 11:24:23 ET More on Palisade Bio Palisade Bio announces 1-for-15 reverse stock split Palisade stock soars 150% on canceled offering, potential reverse split Seeking Alpha’s Quant Rating on Palisade Bio Historical earnings data for Palisade B...
– PALI-2108 in development for the treatment of moderate-to-severe ulcerative colitis (UC) advancing towards Phase 1 clinical study before year end Carlsbad, CA, April 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palis...
A look at the top 10 most actives in the United States Selina Hospitality PLC (SLNA) fell 25.0% to $0.0413 on volume of 65,683,376 shares Auddia Inc. (AUUD) rose 239.8% to $4.8594 on volume of 48,119,148 shares Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 0.4% to $3.375 on volu...
2024-04-08 09:02:03 ET Palisade Bio Inc (PALI) announced stock split at a ratio of 1-for-15 on 2024-04-08 ... Full story available on KlickAnalytics.com
2024-04-03 17:35:43 ET More on Palisade Bio Palisade stock soars 150% on canceled offering, potential reverse split Seeking Alpha’s Quant Rating on Palisade Bio Historical earnings data for Palisade Bio Financial information for Palisade Bio ...
Carlsbad, CA, April 03, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), (“Palisade”, “Palisade Bio” or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoi...
2024-03-27 08:13:00 ET More on Palisade Bio Palisade stock soars 150% on canceled offering, potential reverse split Seeking Alpha’s Quant Rating on Palisade Bio Historical earnings data for Palisade Bio Financial information for Palisade Bio ...
– Rapid advancement of PALI-2108 towards Phase 1 clinical study for the treatment of moderate-to-severe ulcerative colitis; On track to commence Phase 1 before year end – Formation of Clinical Advisory Board – Sufficient cash on hand to execute on business pla...
Carlsbad, CA, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today announced that...
News, Short Squeeze, Breakout and More Instantly...
Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors” with similar structure to PALI-2108 and PALI-1908 This patent family provides Composition o...
Company has now completed murine and non-murine pivotal nonclinical studies using GMP PALI-2108 drug substance Company has successfully formulated enteric-coated tablets of PALI-2108 and has demonstrated consistent and reliable drug release profiles Company on track to commence Ph...
Live video webcast on Wednesday, June 26 th at 4:00 PM ET Carlsbad, CA, June 24, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), biopharmaceutical company focused on developing and advancing novel...